Patent intelligence · US
US 2018264111
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
Patent details — US 2018264111
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 20, 2018
- Expiration
- Sep 15, 2038
- Applicant
- CSL BEHRING GMBH AG [CH]
- CPC classes
- A61K 39/ 395 A I, A61K/39395, A61K/3939591, A61P/1902
Quick answer
US 2018264111 (PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS) is held by CSL BEHRING GMBH AG [CH]. Status: granted. Granted Sep 20, 2018. Expires Sep 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CSL BEHRING GMBH AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K/39395, A61K/3939591, A61P/1902, A61P/1908, A61P/2500
More from CSL BEHRING GMBH AG [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2022258590
PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN
granted -
CA 3198740
METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS
granted -
AU 2017305856
Pharmaceutical formulations of C1 esterase inhibitor
granted -
DK 2928905
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
granted -
CA 3072003
PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND
granted -
CA 3046406
PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES
granted -
CA 3034568
PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE
granted
Frequently asked questions
What is US patent 2018264111?
US 2018264111 (PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS) is held by CSL BEHRING GMBH AG [CH]. Status: granted. Granted Sep 20, 2018. Expires Sep 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2018264111?
CSL BEHRING GMBH AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2018264111 expire?
Our index shows an expiration date of Sep 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.